Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

April 2016

Volume 140Supplement 1S1-S203

Papers and Abstracts of the 8th International Conference on Thrombosis and Hemostasis Issues in Cancer, April 8–10, 2016, Bergamo, Italy

Edited byAnna Falanga, Benjamin Brenner, Frederick R. Rickles

Current Issue
Issues in Progress
Articles in Press
Archive
- Articles in Press
- Archive

Select all

Please select at least one article in order to proceed.

Editorial Board

Published in issue: April 2016

Copyright

Published in issue: April 2016

Preface

Anna Falanga,
Benjamin Brenner,
Frederick R. Rickles

Published in issue: April 2016

ix-x

PAPERS

Simon Karpatkin Memorial Lecture (SKML)

Targeting clotting proteins in cancer therapy – progress and challenges

Wolfram Ruf,
Andrea S. Rothmeier,
Claudine Graf

Published in issue: April 2016

S1-S7

PLENARY SESSIONS

Plenary Session 1: Epidemiology of thrombosis in cancer

Venous thromboembolism and occult cancer: impact on clinical practice

Afshan Gheshmy,
Marc Carrier

Published in issue: April 2016

S8-S11

Cancer associated thrombosis: risk factors and outcomes

Sabine Eichinger

Published in issue: April 2016

S12-S17

Incidental venous thromboembolic events in cancer patients: what we know in 2016

Howard A. Liebman,
Casey O’Connell

Published in issue: April 2016

S18-S20

Plenary Session 2: Role of hemostatic pathways in cancer progression

Microparticles and cancer thrombosis in animal models

Diane Mege,
Soraya Mezouar,
Françoise Dignat-George,
Laurence Panicot-Dubois,
Christophe Dubois

Published in issue: April 2016

S21-S26

Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream

Martin R. Weber,
Masahiko Zuka,
Mihaela Lorger,
...
Patrizia Marchese,
Zaverio M. Ruggeri,
Brunhilde H. Felding

Published in issue: April 2016

S27-S36

PDF
Supplemental Materials

Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy

Esterina D’Asti,
Janusz Rak

Published in issue: April 2016

S37-S43

Heparanase procoagulant activity in cancer progression

Yona Nadir,
Benjamin Brenner

Published in issue: April 2016

S44-S48

Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer

Polymorphisms of the coagulation system and risk of cancer

Mari Tinholt,
Per Morten Sandset,
Nina Iversen

Published in issue: April 2016

S49-S54

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study

Anna Falanga,
Armando Santoro,
Roberto Labianca,,
...
Andrea D’Alessio,
Sandro Barni,
Licia Iacoviello,

HYPERCAN Study Group

Published in issue: April 2016

S55-S59

Plenary Session 4: Hematological malignancies and hemostatic complications

Intracranial hemorrhage in cancer patients treated with anticoagulation

Matthew J. Weinstock,
Erik J. Uhlmann,
Jeffrey I. Zwicker

Published in issue: April 2016

S60-S65

Management of cancer-associated disseminated intravascular coagulation

Marcel Levi

Published in issue: April 2016

S66-S70

Molecular biomarkers of thrombosis in myeloproliferative neoplasms

Tiziano Barbui,
Anna Falanga

Published in issue: April 2016

S71-S75

Update of thrombosis in multiple myeloma

Frank W.G. Leebeek

Published in issue: April 2016

S76-S80

Plenary Session 5: Risk factors for thrombosis in cancer

Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review

Suzanne M. Bleker,
Nick van Es,
Luuk van Gils,
...
Ankie Kleinjan,
Harry R. Büller,
Marcello Di Nisio

Published in issue: April 2016

S81-S88

PDF
Supplemental Materials

Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors)

Giancarlo Castaman

Published in issue: April 2016

S89-S92

Predictors of recurrent venous thromboembolism and bleeding on anticoagulation

Laurel A. Menapace,
Keith R. McCrae,
Alok A. Khorana

Published in issue: April 2016

S93-S98

Special Session: History of ICTHIC

The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence – 15 Years and Counting

Frederick R. Rickles,
Benjamin Brenner,
Anna Falanga

Published in issue: April 2016

S99-S102

Plenary Session 6: Prophylaxis of thrombosis in cancer patients

Primary prophylaxis of VTE in cancer outpatients

Davide Imberti,
Raffaella Benedetti

Published in issue: April 2016

S103-S108

Long-term arterial complications of chemotherapy in patients with cancer

Tone Svilaas,
Joop D. Lefrandt,
Jourik A. Gietema,
Pieter W. Kamphuisen

Published in issue: April 2016

S109-S118

Plenary Session 7: Treatment of cancer-associated thrombosis

Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology

Agnes Y.Y. Lee,
Erica A. Peterson,
Cynthia Wu

Published in issue: April 2016

S119-S127

Management of recurrent venous thromboembolism in cancer patients

Erica Romualdi,
Walter Ageno

Published in issue: April 2016

S128-S131

Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes

Ann Brunson,
Gwendolyn Ho,
Richard White,
Ted Wun

Published in issue: April 2016

S132-S141

Management of bleeding complications in patients with cancer on DOACs

Sam Schulman,
Jeffrey Shrum,
Ammar Majeed

Published in issue: April 2016

S142-S147

Plenary session 8: Open questions in cancer and thrombosis

Anticoagulants versus cancer

Chris Tieken,
Henri H. Versteeg

Published in issue: April 2016

S148-S153

The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?

Simon Noble,
Jessica Sui

Published in issue: April 2016

S154-S159

LMWH in cancer patients with renal impairment – better than warfarin?

Rupert M. Bauersachs

Published in issue: April 2016

S160-S164

Laboratory determination of old and new targeted anticoagulant agents for prevention of bleeding and thrombotic events in cancer patients

Job Harenberg

Published in issue: April 2016

S165-S167

ABSTRACTS

ORAL COMMUNICATIONS

Plenary Session 1: Epidemiology of thrombosis in cancer

OC-01 - Clinical history of cancer patients with isolated distal deep vein thrombosis: a multicenter cohort study

F. Dentali,
S. Pegoraro,
S. Barco,
...
R. Benedetti,
W. Ageno,
M. Di Nisio

Published in issue: April 2016

S168

OC-02 - Risk of arterial thromboembolism in patients with breast cancer

B.B. Navi,
A.S. Reiner,
H. Kamel,
...
M.S.V. Elkind,
K.S. Panageas,
L.M. DeAngelis

Published in issue: April 2016

S169

Plenary Session 2: Role of hemostatic pathways in cancer progression

OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa

G.T. Gerotziafas,
A. Rousseau,
P. van Dreden,
...
A. Khaterchi,
A. Larsen,
I. Elalamy

Published in issue: April 2016

S169

OC-04 - Tissue factor positive microvesicles activate platelets in vitro and in vivo and enhance thrombosis in mice

Y. Hisada,
J.E. Geddings,
Y. Boulaftali,
...
A.S. Wolberg,
W. Bergmeier,
N. Mackman

Published in issue: April 2016

S169-S170

Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer

OC-05 - D-Dimer, fibrinogen and TEG-MA predict thromboembolism in non-small cell lung cancer – interim results from a prospective cohort study

M. Alexander,
R. Wolfe,
D. Ball,
...
B. Solomon,
D. Westerman,
K. Burbury

Published in issue: April 2016

S170

OC-06 - Pro-thrombotic biomarkers in pancreatic diseases: are they specific of cancer?

D. Faille,
N. Ajzenberg,
L. de Chaisemartin,
...
P. Lévy,
P. Ruszniewski,
V. Rebours

Published in issue: April 2016

S170-S171

Plenary Session 4: Hematological malignancies and hemostatic complications

OC-07 - Decoding risk for thromboembolic events in lymphoma patients

D. Antic,
N. Milic,
M. Todorovic,
...
J. Jelicic,
S. Nikolovski,
B. Mihaljevic

Published in issue: April 2016

S171

OC-08 - Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy

C.C.F.M.J. Baaten,
F.C.J.I. Moenen,
Y.M.C. Henskens,
...
E.A.M. Beckers,
J.W.M. Heemskerk,
P.E.J. van der Meijden

Published in issue: April 2016

S171

Plenary Session 5: Risk factors for thrombosis in cancer

OC-09 - Microparticle-mediated transfer of TF hypercoagulability between cancer cells

H. Shaker,
A.S. Rothmeier,
C.C. Kirwan,
W. Ruf

Published in issue: April 2016

S172

OC-10 - Disseminated intravascular coagulation at diagnosis strongly predicts both arterial and venous thrombosis in acute myeloid leukemia patients

E.J. Libourel,
C. Klerk,
Y. van Norden,
...
P. Sonneveld,
B. Löwenberg,
F.W.G. Leebeek

Published in issue: April 2016

S172

Plenary Session 6: Prophylaxis of thrombosis in cancer patients

OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism

A. Young,
J. Phillips,
H. Hancocks,
...
J.A. Dunn,
A. Lokare,
O. Chapman

Published in issue: April 2016

S172-S173

OC-12 - Peri operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice

S. Petch,
L.A. Norris,
S.A. O’Toole,
N. Gleeson,
F. Abu Saadeh

Published in issue: April 2016

S173

Plenary Session 7: Treatment of cancer-associated thrombosis

OC-13 - Safe and effective use of direct oral anticoagulants (DOAC) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism

J.A. Ross,
M. Miller,
C.R. Hernandez

Published in issue: April 2016

S173-S174

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin

C.I. Piatek,
S.T. Tagawa,
D. Wei-Tsai,
...
L. Rochanda,
S. Groshen,
H.A. Liebman

Published in issue: April 2016

S174

Plenary Session 8: Open questions in cancer and thrombosis

OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism

B. Cosmi,
C. Legnani,
A. Ghirarduzzi,
...
P. Prandoni,
G. Palareti
on behalf of FCSA, Italian Federation of Anticoagulation Clinics

Published in issue: April 2016

S174

OC-16 - Neutrophil extracellular traps and tissue factor-bearing microvesicles: a liaison dangereuse causing overt DIC in cancer patients?

L. Hell,
J. Thaler,
K. Martinod,
...
F. Posch,
D.D. Wagner,
I. Pabinger

Published in issue: April 2016

S174-S175

POSTERS

Poster Session 1: Epidemiology and risk assessment

PO-01 - Congestive heart failure is an independent risk factor for venous thromboembolism and mortality in cancer patients

O. Königsbrügge,
J. Riedl,
E. Grilz,
...
C. Zielinski,
I. Pabinger,
C. Ay

Published in issue: April 2016

S176

PO-02 - Retrospective audit of the Peripherally Inserted Central Catheter (PICC) associated thrombosis in patients with haematological malignancies at Cork University Hospital

E. McAuliffe,
S. O’Shea,
M.I. Khan

Published in issue: April 2016

S176

PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)

R.M. Santi,
M. Ceccarelli,
G. Catania,
...
L. Contino,
G. Ciccone,
M. Ladetto

Published in issue: April 2016

S177

Results per page:50

Popular Articles

April 2016

Preface

PAPERS

Simon Karpatkin Memorial Lecture (SKML)

PLENARY SESSIONS

Plenary Session 1: Epidemiology of thrombosis in cancer

Plenary Session 2: Role of hemostatic pathways in cancer progression

Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer

Plenary Session 4: Hematological malignancies and hemostatic complications

Plenary Session 5: Risk factors for thrombosis in cancer

Special Session: History of ICTHIC

Plenary Session 6: Prophylaxis of thrombosis in cancer patients

Plenary Session 7: Treatment of cancer-associated thrombosis

Plenary session 8: Open questions in cancer and thrombosis

ABSTRACTS

ORAL COMMUNICATIONS

Plenary Session 1: Epidemiology of thrombosis in cancer

Plenary Session 2: Role of hemostatic pathways in cancer progression

Plenary Session 3: Old and emerging biomarkers for thrombosis and disease progression in cancer

Plenary Session 4: Hematological malignancies and hemostatic complications

Plenary Session 5: Risk factors for thrombosis in cancer

Plenary Session 6: Prophylaxis of thrombosis in cancer patients

Plenary Session 7: Treatment of cancer-associated thrombosis

Plenary Session 8: Open questions in cancer and thrombosis

POSTERS

Poster Session 1: Epidemiology and risk assessment